Second-line combination antiretroviral therapy in resource-limited settings: Facing the challenges through clinical research

AIDS

Volumn 21, Issue SUPPL. 4, 2007, Pages

  Boyd, Mark A ^a   Cooper, David A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

AIDS; Antiretroviral therapy; Developing world; HIV; Protease inhibitor; Resource limited; Second line

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; COMBINATION CHEMOTHERAPY; DEVELOPING COUNTRY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FUNDING; HEALTH CARE ACCESS; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMEDICAL RESEARCH; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; HEALTH CARE RATIONING; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MEDICALLY UNDERSERVED AREA;

EID: 34447338043     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000279707.01557.b2     Document Type: Article

References (64)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19.
4. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
5. Schwartlander B, Grubb I, Perriens J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 2006; 368:541-546.
6. United Nations General Assembly. Declaration of Commitment on HIV/AIDS: "lobal Crisis-Global Action". Available at: http://www.un.org/ga/aids/coverage/FinalDeclarationHIVAIDS.html. Accessed: 13 February 2007.
7. World Health Organization. HIV/AIDS Programme. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health response. Available at: http://www.who.int/entity/hiv/pub/guidelines/artadultguidelines.pdf. Accessed: 14 February 2007.
8. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
9. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, M'Bangue M, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis 2005; 41:108-111.
10. Bisson GP, Frank I, Gross R, Re VL III, Strom JB, Wang X, et al. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 2006; 20:1333-1336.
11. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
12. Colebunders R, Kamya M, Semitala F, Castelnuovo B, Katabira E, McAdam K. Free antiretrovirals must not be restricted only to treatment-naive patients. Experience in Uganda suggests that restricting access is not the way forward. PLoS Med 2005; 2:e276.
13. Médicins Sans Frontières. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. Available at: http://www.accessmed-msf.org/documents/ untanglingtheweb%209.pdf. Accessed: 7 February 2007.
14. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
15. MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125-2135.
16. Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368:287-298.
17. Zhou J, Paton NI, Ditangco R, Chen Y-MA, Kamarulzaman A, Kumarasamy N, et al. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med 2007; 8:8-16.
18. Stevens W, Kaye S, Corrah T. Antiretroviral therapy in Africa. BMJ 2004; 328:280-282.
19. Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis 2005; 41:376-385.
20. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
21. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
22. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
23. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
24. Zhou J, Kumarasamy N. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2005; 6:216-223.
25. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20:1163-1169.
26. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447-454.
27. Anabwani G, Navario P. Nutrition and HIV/AIDS in sub-Saharan Africa: an overview. Nutrition 2005; 21:96-99.
28. Mayo J, Collazos J, Martinez E, Ibarra S. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med 2002; 162:1095-1098.
29. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006; 368:1254-1259.
30. Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis 2006; 6:483-495.
31. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-1580.
32. Raviglione MC, Smith IM. XDR tuberculosis - implications for global public health. N Engl J Med 2007; 356:656-659.
33. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
34. Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 2006; 20:1497-1502.
35. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
36. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
37. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989.
38. Hakim J, on behalf of the DART Trial Team. A structured treatment interruption (STI) strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART trial. In: Program and abstracts of the XVIth International AIDS Conference. Toronto, Canada, 13-18 August 2006 [Abstract THLB0207].
39. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, et al. Efficacy of a twice-daily antiretroviral regimen containing 100mg ritonavir/400mg indinavir in HIV-infected patients. AIDS 2003; 17:209-214.
40. Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, et al. Efficacy and safety of ritonavir/indinavir 100/400mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir Ther 2003; 8:603-609.
41. Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100mg twice daily in HIV-1-infected Thai patients. Antivir Ther 2005; 10:301-307.
42. 3: 96-week outcomes. Antivir Ther 2005; 10:911-916.
43. Konopnicki D, De Wit S, Poll B, Crommentuyn K, Huitema A, Clumeck N. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100mg and 400/100 mg twice daily. HIV Med 2005; 6:1-6.
44. Cressey TR, Leenasirimakul P, Jourdain G, Tod M,Sukrakanchana PO, Kunkeaw S, et al. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J Antimicrob Chemother 2005; 55:1041-1044.
45. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-F9.
46. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32:18-29.
47. Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, Walker UA, et al. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004; 18:955-957.
48. Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-287.
49. Nunes EP, Oliveira MS, Almeida MM, Pilotto JH, Ribeiro JE, Faulhaber JC, et al. 48-Week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/ml on HAART - the KalMo study. In: Program and abstracts of the XVIth International AIDS Conference. Toronto, Canada, 13-18 August 2006 [Abstract TUAB0103].
50. Cameron W, da Silva B, Arribas J, Myers R, Bellos N, Gilmore N, et al. A two-year randomized controlled clinical trial in antiretroviral-naive subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (Study M03-613). In: Program and abstracts of the XVIth International AIDS Conference. Toronto, Canada, 13-18 August 2006 [Abstract THLB0201].
51. Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814.
52. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44:417-422.
53. Delfraissy JF, Flandre P, Delaugerre C, Horban A, Girard PM, Rouzioux C, et al. MONARK trial (MONotherapy AntiRetroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r R zidovudine/lamivudine in antiretroviral naive patients. In: Program and abstracts of the XVIth International AIDS Conference. Toronto, Canada, 13-18 August 2006 [Abstract THLB0202].
54. Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, et al. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir Ther 2006; 11:631-635.
55. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
56. Schooley RT. Viral load testing in resource-limited settings. Clin Infect Dis 2007; 44:139-140.
57. Safreed-Harmon K, Cooper DA, Lange JM, Duncombe C, Phanuphak P. The HIV Netherlands Australia Thailand research collaboration: lessons from 7 years of clinical research. AIDS 2004; 18:1971-1978.
58. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19:185-192.
59. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51:1231-1238.
60. Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M Jr, et al. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genom 2006; 16:321-329.
61. Bunnell R, Mermin J, De Cock KM. HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA 2006; 296:855-858.
62. Ruxin J, Paluzzi JE, Wilson PA, Tozan Y, Kruk M, Teklehaimanot A. Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines. Lancet 2005; 365:618-621.
63. Feeley F. Fight AIDS as well as the brain drain. Lancet 2006; 368:435-436.
64. Kober K, Van Damme W. Scaling up access to antiretroviral treatment in southern Africa: who will do the job? Lancet 2004; 364:103-107.